| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10013972 | HBV | ENSG00000069535.14 | protein_coding | MAOB | No | No | 4129 | P27338 |
| TVIS20025210 | HPV | ENSG00000069535.14 | protein_coding | MAOB | No | No | 4129 | P27338 |
| TVIS20068158 | HPV | ENSG00000069535.14 | protein_coding | MAOB | No | No | 4129 | P27338 |
| TVIS20064192 | HPV | ENSG00000069535.14 | protein_coding | MAOB | No | No | 4129 | P27338 |
| TVIS20020700 | HPV | ENSG00000069535.14 | protein_coding | MAOB | No | No | 4129 | P27338 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | MAOB |
|---|---|
| DrugBank ID | DB01037 |
| Drug Name | Selegiline |
| Target ID | BE0002196 |
| UniProt ID | P27338 |
| Regulation Type | inhibitor |
| PubMed IDs | 11752352; 1794016; 9673855; 12199263; 16034956; 6441926; 7995016; 11978145; 16641841; 17715422; 19300583; 17823646; 16099847 |
| Citations | Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.@@Chrisp P, Mammen GJ, Sorkin EM: Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease. Drugs Aging. 1991 May;1(3):228-48.@@Heinonen EH, Myllyla V: Safety of selegiline (deprenyl) in the treatment of Parkinson's disease. Drug Saf. 1998 Jul;19(1):11-22.@@Authors unspecified: Selegiline: a second look. Six years later: too risky in Parkinson's disease. Prescrire Int. 2002 Aug;11(60):108-11.@@Macleod AD, Counsell CE, Ives N, Stowe R: Monoamine oxidase B inhibitors for early Parkinson's disease. Cochrane Database Syst Rev. 2005 Jul 20;(3):CD004898.@@Magyar K, Tothfalusi L: Pharmacokinetic aspects of deprenyl effects. Pol J Pharmacol Pharm. 1984 Jul-Aug;36(4):373-84.@@Heinonen EH, Anttila MI, Lammintausta RA: Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites. Clin Pharmacol Ther. 1994 Dec;56(6 Pt 2):742-9.@@Deleu D, Northway MG, Hanssens Y: Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet. 2002;41(4):261-309.@@Patkar AA, Pae CU, Masand PS: Transdermal selegiline: the new generation of monoamine oxidase inhibitors. CNS Spectr. 2006 May;11(5):363-75.@@Azzaro AJ, Ziemniak J, Kemper E, Campbell BJ, VanDenBerg C: Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules. J Clin Pharmacol. 2007 Oct;47(10):1256-67. Epub 2007 Aug 22.@@Lee KC, Chen JJ: Transdermal selegiline for the treatment of major depressive disorder. Neuropsychiatr Dis Treat. 2007;3(5):527-37.@@Baker GB, Sowa B, Todd KG: Amine oxidases and their inhibitors: what can they tell us about neuroprotection and the development of drugs for neuropsychiatric disorders? J Psychiatry Neurosci. 2007 Sep;32(5):313-5.@@Andoh T, Chock PB, Murphy DL, Chiueh CC: Role of the redox protein thioredoxin in cytoprotective mechanism evoked by (-)-deprenyl. Mol Pharmacol. 2005 Nov;68(5):1408-14. doi: 10.1124/mol.105.012302. Epub 2005 Aug 12. |
| Groups | Approved; Investigational; Vet_approved |
| Direct Classification | Amphetamines and derivatives |
| SMILES | C[C@H](CC1=CC=CC=C1)N(C)CC#C |
| Pathways | |
| PharmGKB | PA451316 |
| ChEMBL | CHEMBL972 |
